The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
A Randomized Trial of High-Dose Compared with Low-Dose Omega-3 Fatty Acids in Severe IgA Nephropathy
Abstract
Abstract.: Tested was the hypothesis that high-dose omega (ω)-3 fatty acids will be more effective than low-dose ω-3 fatty acids in preserving renal function in patients with severe IgA nephropathy in a randomized, open-label, parallel-group clinical trial. Patients were assigned to receive either high-dose fatty acids (EPA 3.76 g and DHA 2.94 g) or low-dose fatty acids (EPA 1.88 g and DHA 1.47 g), both given daily in a highly purified ethyl ester concentrate (Omacor). Patients were treated for a minimum of 2 yr in the absence of a treatment failure or until study closure (January 2000). Seventy-three patients were enrolled in the trial with two ranges of elevated serum creatinine (SC): 63 patients (86%) with a range of 1.5 to 2.9 mg/dl and 10 patients (14%) with a range of 3.0 to 4.9 mg/dl. The primary end point, within-patient rates of change in SC (2-yr minimum), showed an annualized median increase in SC of 0.08 mg/dl per yr in the low-dose group and 0.10 mg/dl per yr in the high-dose group (P = 0.51). Patients in the lower entry SC range had lower SC slopes (P = 0.02) and less end-stage renal disease (ESRD) (P < 0.001) compared with those in the higher entry SC range. No patient died, and 18 patients developed ESRD: 10 in the low-dose group and 8 in the high-dose group (P = 0.56). SC slopes were significantly lower, and survival free of ESRD was significantly higher (both, P = 0.04) in the 63 Omacor-treated patients compared with the 22 placebo-treated patients from our previously reported clinical trial in which both groups had a similar level of renal impairment. Patient compliance was excellent, and no serious adverse events were noted. Low-dose and high-dose ω-3 fatty acids were similar in slowing the rate of renal function loss in high-risk patients with IgA nephropathy, particularly those with moderately advanced disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A RAPID METHOD OF TOTAL LIPID EXTRACTION AND PURIFICATION
Bligh, E. G., & Dyer, W. J. (1959) · Canadian Journal of Biochemistry and Physiology · doi:10.1139/o59-099 · Cited by 54,751
Cited by
Interventions for enhancing medication adherence
Nieuwlaat, R., Wilczynski, N., Navarro, T., Hobson, N., Jeffery, R., Keepanasseril, A., Agoritsas, T., Mistry, N., Iorio, A., Jack, S., et al. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000011.pub4 · Cited by 2,945
Interventions for enhancing medication adherence
Haynes, R. B., Ackloo, E., Sahota, N., McDonald, H. P., & Yao, X. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000011.pub3 · Cited by 1,244
Donadio, J. V., & Grande, J. P. (2002) · New England Journal of Medicine · doi:10.1056/nejmra020109 · Cited by 661
Self-citationInterventions for enhancing medication adherence
Haynes, R., Yao, X., Degani, A., Kripalani, S., Garg, A., & McDonald, H. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000011.pub2 · Cited by 517
Lai, K. N., Tang, S. C. W., Schena, F. P., Novak, J., Tomino, Y., Fogo, A. B., & Glassock, R. J. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.1 · Cited by 508
Metadata
- Authors
- DONADIO, J. V., LARSON, T. S., BERGSTRALH, E. J., & GRANDE, J. P.
- Venue
- Journal of the American Society of Nephrology
- Published
- 2001-04
- Volume
- 12
- Issue
- 4
- Pages
- 791-799
- ISSN
- 1046-6673 (ISSN-L)
- OpenAlex
- W2150318937
- Cited by
- 160
- References
- 1
- FWCI
- 6.71
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Randomized Trial of High-Dose Compared with Low-Dose Omega-3 Fatty Acids in Severe IgA Nephropathy. https://app.cochat.ai/papers/10.1681/asn.v124791
- The paper
- DONADIO, J. V., LARSON, T. S., BERGSTRALH, E. J., & GRANDE, J. P. (2001). A Randomized Trial of High-Dose Compared with Low-Dose Omega-3 Fatty Acids in Severe IgA Nephropathy. Journal of the American Society of Nephrology. https://doi.org/10.1681/asn.v124791
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.